OpenLB
Open Library of Bioscience
Advanced Search
Antimicrobial agents and chemotherapy
Dec, 2014;58 (12): 7541-4.

Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.

Georgia Vrioni, Adamantios Bourdakis, Georgios Pappas, Vassiliki Pitiriga, Maria Mavrouli, Spyros Pournaras, Athanassios Tsakris
Author Information
  1. Georgia Vrioni: Department of Microbiology, Medical School, University of Athens, Athens, Greece.
  2. Adamantios Bourdakis: Department of Internal Medicine, Trikala General Hospital, Trikala, Greece.
  3. Georgios Pappas: Institute of Continuing Medical Education of Ioannina, Ioannina, Greece.
  4. Vassiliki Pitiriga: Department of Microbiology, Medical School, University of Athens, Athens, Greece.
  5. Maria Mavrouli: Department of Microbiology, Medical School, University of Athens, Athens, Greece.
  6. Spyros Pournaras: Department of Microbiology, Medical School, University of Athens, Athens, Greece spournaras@med.uoa.gr.
  7. Athanassios Tsakris: Department of Microbiology, Medical School, University of Athens, Athens, Greece.
PMID: 25246401 DOI: 10.1128/AAC.03841-14

Abstract

The effects of doxycycline-streptomycin-rifampin versus a standard doxycycline-streptomycin regimen on residual Brucella DNA were compared in 36 acute brucellosis patients. At admission, all patients given triple (n = 22) and double (n = 14) regimens had detectable Brucella DNA with similar mean loads (P = 0.982). At follow-up, 14 to 20 months postpresentation, significantly more patients receiving triple than double regimens had undetectable Brucella DNA (P = 0.026). The doxycycline-streptomycin-rifampin regimen eliminates Brucella DNA more efficiently than doxycycline-streptomycin, which may result in superior long-term clearance of Brucella.

References

  1. Clin Microbiol Infect. 2008 Dec;14(12):1128-34 [PMID: 19046166]
  2. Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S8-11 [PMID: 20696557]
  3. PLoS Med. 2007 Dec;4(12):e317 [PMID: 18162038]
  4. N Engl J Med. 2005 Jun 2;352(22):2325-36 [PMID: 15930423]
  5. Lancet Infect Dis. 2006 Feb;6(2):91-9 [PMID: 16439329]
  6. J Clin Rheumatol. 2004 Dec;10(6):300-7 [PMID: 17043537]
  7. Clin Infect Dis. 2008 Jun 15;46(12):e131-6 [PMID: 18462106]
  8. J Trop Med Hyg. 1992 Aug;95(4):271-5 [PMID: 1495123]
  9. Am J Trop Med Hyg. 2007 Apr;76(4):698-702 [PMID: 17426173]
  10. Expert Rev Anti Infect Ther. 2011 Jul;9(7):833-45 [PMID: 21810055]
  11. BMJ. 2008 Mar 29;336(7646):701-4 [PMID: 18321957]
  12. Microbes Infect. 2011 Feb;13(2):134-42 [PMID: 21034846]
  13. Monogr Ser World Health Organ. 1975;(55):1-163 [PMID: 812265]
  14. Euro Surveill. 2011 Nov 10;16(45): [PMID: 22114980]
  15. J Clin Microbiol. 2009 Jul;47(7):2084-9 [PMID: 19420176]
  16. Ann Thorac Cardiovasc Surg. 2002 Dec;8(6):381-5 [PMID: 12517300]
  17. Clin Infect Dis. 2006 May 1;42(9):1266-73 [PMID: 16586386]
  18. BMJ. 2008 Mar 29;336(7646):678-9 [PMID: 18321958]

MeSH Term

Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Bacterial Load
Brucella melitensis
Brucellosis
DNA, Bacterial
Doxycycline
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Prospective Studies
Rifampin
Streptomycin

Chemicals

Anti-Bacterial Agents
DNA, Bacterial
Doxycycline
Rifampin
Streptomycin
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0BrucellaDNA=regimenpatientstripledoubledoxycycline-streptomycin-rifampinversusstandarddoxycycline-streptomycinbrucellosisn14regimensP0eliminatesefficientlyeffectsresidualcompared36acuteadmissiongiven22detectablesimilarmeanloads982follow-up20monthspostpresentationsignificantlyreceivingundetectable026mayresultsuperiorlong-termclearanceAdministrationantimicrobialhumanbacterialload

Similar Articles

Cited By